Protocol Ledger

NCT05748171 · Phase II · RECRUITING

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

Interventional Phase II clinical trial protocol NCT05748171 sponsored by Pfizer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-05-17 Enrollment: 100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05748171
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05748171
Protocol FieldVerified Registry Value
NCT IdentifierNCT05748171
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment100 participants (ESTIMATED)
Registered Start Date2023-05-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05748171
Hospital Research SiteLocationSite Profile
Cliniques Universitaires Saint-LucBrussels, BelgiumOpen Hospital Dossier ->
UZ GentGhent, BelgiumOpen Hospital Dossier ->
UZ LeuvenLeuven, BelgiumOpen Hospital Dossier ->
RigshospitaletCopenhagen, DenmarkOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI